既往雄激素使用者血清INSL3水平降低提示间质细胞功能受损
这项社区横断面研究纳入18-50岁男性,比较从未使用、当前使用和既往使用合成雄激素类固醇(AAS)者的血清胰岛素样因子3(INSL3)。当前和既往使用者INSL3均低于对照组,既往使用者即使调整睾酮后仍较低,且与累积使用时长相关,提示停用多年后间质细胞分泌能力仍受损。
要点
- 当前和既往AAS使用者血清INSL3均显著低于从未使用者。
- 既往使用者停用平均32个月后INSL3仍低,且独立于血清总睾酮。
- INSL3与睾丸体积相关,而抑制素B和睾酮无此关联。
核心结论
- 男性停用AAS数年后血清INSL3仍降低,且独立于睾酮,提示间质细胞能力持续受损。
研究设计与样本
- 社区横断面研究纳入18-50岁进行休闲力量训练的男性,分为从未使用AAS对照组(n=44)、当前使用者(n=46)和既往使用者(n=42),既往使用者距停药平均32(23;45)个月。
主要发现
- 当前和既往AAS使用者血清INSL3中位数(四分位距)分别为0.04 µg/L(检测不到-0.07 µg/L)和0.39 µg/L(0.24-0.62 µg/L),均低于对照组的0.59 µg/L(0.45-0.72 µg/L),P小于.001。
- 多变量线性回归显示,既往使用者血清INSL3仍低于对照组,B(95%CI)为-0.16 µg/L(-0.29至-0.04 µg/L),P等于.011,即使调整血清总睾酮和其他相关混杂因素后仍显著。
- 在该模型中INSL3与总睾酮无关联,P等于.821。
- 既往使用者中较长的累积AAS使用时长(log2)与较低血清INSL3相关,B(95%CI)为-0.08(-0.14至-0.01),P等于.022。
- 多变量线性回归中,血清INSL3与睾丸大小相关,B(95%CI)为4.7(0.5至8.9),P等于.030,而抑制素B和睾酮与睾丸大小无此关联。
临床怎么用
- 对既往AAS使用者评估睾丸功能时,INSL3可能较睾酮更敏感地反映间质细胞分泌能力受损。
- 询问AAS使用史及累积使用时长有助于识别间质细胞功能持续受损的高风险男性。
局限性
- 为社区横断面研究,无法确立因果关系。
- 样本量有限,且仅纳入进行休闲力量训练的18-50岁男性,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Illicit use of anabolic androgenic steroids (AAS) is frequently observed in men and is associated with subsequent testosterone deficiency although the long-term effect on gonadal function is still unclear. Serum insulin-like factor 3 (INSL3) has been suggested to be a superior biomarker of Leydig cell secretory capacity compared to testosterone. OBJECTIVE: This study aimed to investigate serum INSL3 concentrations in AAS users. METHODS: This community-based, cross-sectional study included men aged 18 to 50 years, involved in recreational strength training and allocated to 1 of 3 groups: never-AAS users as controls (n = 44), current (n = 46), or former AAS users (n = 42) with an average duration since AAS cessation of 32 (23 ; 45) months. RESULTS: Serum INSL3 was lower in current AAS users and former AAS users than in controls, median (interquartile range), 0.04 µg/L (nondetectable [ND]-0.07 µg/L) and 0.39 µg/L (0.24-0.62 µg/L) vs 0.59 µg/L (0.45-0.72 µg/L), P less than .001. Former AAS users exhibited lower serum INSL3 levels than controls in a multivariable linear regression even after adjusting for serum total testosterone (TT) and other relevant confounders, (B) (95% CI), -0.16 µg/L (95% CI, -0.29 to -0.04 µg/L), P equal to .011. INSL3 and TT were not associated in the model, P equal to .821. Longer accumulated AAS duration (log2) was associated with lower serum INSL3 in former AAS users, (B) (95% CI), -0.08 (95% CI, -0.14 to -0.01), P equal to .022. Serum INSL3, but not inhibin B or testosterone, was associated with testicular size in a multivariate linear regression, (B) (95% CI); 4.7 (95% CI, 0.5 to 8.9), P equal to .030. CONCLUSION: Serum INSL3 is reduced years following AAS cessation in men, independently of testosterone, suggesting persistently impaired Leydig cell capacity.
引用
- Rasmussen JJ, Albrethsen J, Frandsen MN, et al. Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity. J Clin Endocrinol Metab. 2021. PMID: 33693710. doi:10.1210/clinem/dgab129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。